Oramed Pharmaceuticals Inc. (ORMP)
|Address:1185 Avenue Of The Americas, 3Rd Floor
New York, New York 10036
|Phone||844 967 2633|
|Fiscal Year||September - August|
|Reporting Currency||US Dollars|
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides.
Its proprietary flagship product is the ORMD-0801, an orally ingestible insulin capsule, which completed phase II clinical trials for the treatment of individuals with diabetes.
It is also developing ORMD-0901, an oral glucagon-like peptide-1 capsule that has completed phase I clinical trials for the treatment of type 2 diabetes; and a weight loss treatment in the form of an oral leptin capsule.
The company was formerly known as Integrated Security Technologies, Inc. and changed its name to Oramed Pharmaceuticals Inc. in April 2006. Oramed Pharmaceuticals Inc. was founded in 2002 and is based in New York, New York.
|Nadav Kidron||President, Chief Executive Officer and Executive Director|
|Avraham Gabay||Chief Financial Officer, Treasurer and Secretary|
|Joshua Hexter||Chief Operating and Business Officer|
|Dr. Miriam Kidron||Chief Scientific Officer and Director|
|Dr. Roy Eldor M.D., Ph.D.||Chief Medical Advisor and Member of the Scientific Advisory Board|
Latest SEC Filings
|Jun 16, 2021||8-K||Current report|
|Jun 16, 2021||424B5||Prospectus [Rule 424(b)(5)]|
|Jun 16, 2021||S-3MEF||Registration adding securities to prior Form S-3 registration [Rule 462(b)]|
|May 25, 2021||8-K||Current report|
|May 10, 2021||8-K||Current report|
|Apr 13, 2021||10-Q||Quarterly report [Sections 13 or 15(d)]|
|Mar 23, 2021||8-K||Current report|
|Mar 19, 2021||8-K||Current report|
|Mar 2, 2021||4||Statement of changes in beneficial ownership of securities|
|Feb 17, 2021||4||Statement of changes in beneficial ownership of securities|
|View All SEC filings|